Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients

Pharmacogenetics and Genomics

Volumn 24, Issue 1, 2014, Pages 26-34

  Ternant, David ^a,b   Büchler, Matthias ^d   Thibault, Gilles ^a,c   Ohresser, Marc ^a   Watier, Hervé ^a,c   Lebranchu, Yvon ^d   Paintaud, Gilles ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c Laboratory of Immunology   (France)

^d Laboratory of Immunology ^*  (France)

Author keywords

Antithymocyte globulins; Dose response relationship; Immunoglobulin G receptors; Kidney transplantation; Pharmacogenetics

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; DOSE TIME EFFECT RELATION; FCGR3A GENE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RATE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T CELL DEPLETION; T LYMPHOCYTE RECEPTOR GENE; TURNOVER TIME; YOUNG ADULT;

ADULT; AGED; ANIMALS; ANTIGENS, CD3; ANTILYMPHOCYTE SERUM; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RABBITS; RECEPTORS, IGG; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; VALINE; YOUNG ADULT;

EID: 84890923836     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000017     Document Type: Article

References (35)

1. Muller TF, Grebe SO, Neumann MC, Heymanns J, Radsak K, Sprenger H, et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997; 64: 1432-1437. (Pubitemid 27513622)
2. Oertel M, Sack U, Kohlhaw K, Lehmann I, Emmrich F, Berr F, et al. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study. Transpl Int 2002; 15: 463-471. (Pubitemid 36061740)
3. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360-2368. (Pubitemid 28155510)
4. Michallet MC, Saltel F, Preville X, Flacher M, Revillard JP, Genestier L. Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood 2003; 102: 3719-3726. (Pubitemid 37409393)
5. Preville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460-468. (Pubitemid 32175986)
6. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114. (Pubitemid 27314146)
7. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758. (Pubitemid 34525533)
8. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947. (Pubitemid 46606207)
9. ZhangW, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712-3718. (Pubitemid 47372612)
10. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796.
11. Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 511-519. (Pubitemid 38387177)
12. Ternant D, Buchler M, Beneton M, Alvan G, Ohresser M, Touchard G, et al. Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcgammaRIIIa genetic polymorphism. Br J Clin Pharmacol 2008; 65: 60-68. (Pubitemid 350265164)
13. Buchler M, Thibault G, al Najjar A, Valentin JF, Guerraoui A, Nivet H, et al. Monitoring of ATG therapy by flow cytometry and lymphocyte counts in renal transplantation. Transplant Proc 1996; 28: 2817-2818. (Pubitemid 26339516)
14. Dall'Ozzo S, Andres C, Bardos P, Watier H, Thibault G. Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods 2003; 277: 185-192. (Pubitemid 36694384)
15. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, et al. Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Transplant Proc 1999; 31:16S-18S. (Pubitemid 29238870)
16. Esposito L, Kamar N, Tkaczuk J, Abbal M, Durand D, Rostaing L. Long-term evolution of lymphocytes subsets after induction therapy based on continuous versus discontinuous administration of anti-thymocyte globulins in renal-transplant patients. Transplant Proc 2005; 37: 785-787. (Pubitemid 40590700)
17. Louis S, Audrain M, Cantarovich D, Schaffrath B, Hofmann K, Janssen U, et al. Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids. Transplantation 2007; 83: 712-721. (Pubitemid 46569188)
18. Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, et al. Altered balance between effector T cells and FOXP3+ HELIOS + regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int 2012; 25: 1257-1267.
19. Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P, Steimer JL, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 2007; 34: 57-85. (Pubitemid 46122548)
20. Henin E, You B, VanCutsem E, Hoff PM, Cassidy J, Twelves C, et al. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther 2009; 85: 418-425.
21. SAS. Monolix 4.2.2 user's guide. Orsay, France: Lixoft SAS 2013; Available at: http://www.lixoft.eu/wp-content/resources/docs/UsersGuide.pdf. [Accessed 27 July 2013].
22. Handelsman DJ. Optimal power transformations for analysis of sperm concentration and other semen variables. J Androl 2002; 23: 629-634. (Pubitemid 34977518)
23. Fox J,Weisberg S, Bates D, Ellison S. Package 'car' for R (Version 2.0-18). Available at: http://cran.r-project.org/web/packages/car/car.pdf. [Accessed 13 August 2013].
24. R Development Core Team. R 2.7.1. R: A language and environment for statistical computing. ISBN 3-900051-07-0. Vienna, Austria: R Foundation for Statistical Computing 2010. Available at: http://www.R-project.org. [Accessed 13 August 2013].
25. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde addon package for R. Comput Methods Programs Biomed 2008; 90: 154-166.
26. Kakhniashvili I, Filicko J, Kraft WK, Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34+ -selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2005; 11: 609-618. (Pubitemid 41001636)
27. Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003; 9: 460-471. (Pubitemid 38351804)
28. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64: 4664-4669. (Pubitemid 38856941)
29. Vance BA, Huizinga TW, Wardwell K, Guyre PM. Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. J Immunol 1993; 151: 6429-6439. (Pubitemid 23340389)
30. Bieber CP, Griepp RB, Oyer PE, Wong J, Stinson EB. Use of rabbit antithymocyte globulin in cardiac transplantation. Relationship of serum clearance rates to clinical outcome. Transplantation 1976; 22: 478-488.
31. Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996; 45: 29-32. (Pubitemid 26032738)
32. Guttmann RD, Caudrelier P, Alberici G, Touraine JL. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc 1997; 29:24S-26S.
33. Buchler M, Longuet H, Lemoine R, Herr F, Gatault P, Thibault G, et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. Transpl Immunol 2013; 28: 120-126.
34. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-4721. (Pubitemid 36025290)
35. Quartino AL, Friberg LE, Karlsson MO. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs 2010; 30: 833-845.